

Cumulative Index of PhVWP Monthly Reports	
Topic Title	Issue Number
1 st EMA Scientific Workshop on Nanomedicines on 2-3 September 2010	1009
Acepromazine: Antipsychotics - Risk of venous thromboembolism	0910
Acetylsalicylic acid: Dipyridamole in combination with acetylsalicylic acid – No evidence for increased risk of ischaemic stroke versus acetylsalicylic acid alone in the European population	1004
Active substances with a known risk of Stevens-Johnson syndrome and toxic epidermal necrolysis	1109
Adrenaline-containing auto-injectors EPIPEN/ALTELLUS – Risk of failure of self-injection due to labelling	1010
Alendronic acid: Bisphosphonates for oral use – Risk of oesophageal irritation but insufficient evidence on causal relationship with oesophageal cancer	1207
Alendronic acid: Bisphosphonates for oral use – Risk of oesophageal irritations but insufficient evidence to conclude a causal relationship with oesophageal cancer	1010
Allopurinol – Risk of skin reactions associated with HLA-B*5801 allele	1207
Allopurinol: Active substances with a known risk of Stevens-Johnson syndrome and toxic epidermal necrolysis	1109
ALTELLUS: Adrenaline-containing auto-injectors – Risk of failure of self-injection due to labelling	1010
Amisulpiride: Antipsychotics - Risk of venous thromboembolism	0910
Amitriptyline: Antidepressants – Risk of bone fractures	1003
Antidepressants – Risk of bone fractures	1003
Antiepileptics – Risk of bone disorders	1110
Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Antipsychotics - Risk of venous thromboembolism	0910
Apomorphine - Risk of QT interval prolongation	0909
Apomorphine: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Atomoxetine – Updated information on effects on blood pressure and heart rate	1111
Atorvastatin: HMG-CoA reductase inhibitors - Risks of sleep disturbances, memory loss, sexual dysfunction, depression, interstitial lung disease and micturition disorders	0911
Atorvastatin: Fusidic acid – Risk of rhabdomyolysis due to interaction with HMG-CoA reductase inhibitors	1107
Atorvastatin: HMG-CoA reductase inhibitors - Risk of new onset diabetes	1112
Bambuterol: Short-acting beta agonists - Risk of myocardial ischaemia	0910
Beclometasone: Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1011
Befunolol: Beta-blockers for ophthalmic use – Risk of systemic adverse reactions	1106
Benperidol: Antipsychotics - Risk of venous thromboembolism	0910
Benserazide: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Benzodiazepines: Prazepam – Not contraindicated in glaucoma	1207
Benzydamine – Risk of adverse reactions after incorrect oral intake	1009
Beta agonists, short-acting - Risk of myocardial ischaemia	0910
Beta-blockers for ophthalmic use – Risk of systemic adverse reactions	1106
Betamethasone: Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1011
Betaxolol: Beta-blockers for ophthalmic use – Risk of systemic adverse reactions	1106
Bisphosphonates for oral use – Risk of oesophageal irritation but insufficient evidence on causal relationship with oesophageal cancer	1207
Bisphosphonates for oral use – Risk of oesophageal irritations but insufficient evidence to conclude a causal relationship with oesophageal cancer	1010
Blue dyes (e.g. Patent Blue V, Sulphan Blue) – Risk of serious allergic reactions	1204
BRICANYL TURBOHALER (or BRICANYL TURBUHALER) (terbutaline) – Effect of physical impact on accuracy of dose delivery and recommended 100 dose pack size	1104
Bromocriptine: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Bromoperidol: Antipsychotics - Risk of venous thromboembolism	0910
Budesonide (PULMICORT TURBOHALER or PULMICORT TURBUHALER): Effect of physical impact on accuracy of dose delivery and recommended 100 dose pack size for BRICANYL TURBOHALER (terbutaline)	1104
Budesonide: Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1011
Bumetanide: High-ceiling diuretics – Evidence does not confirm risk of basal cell carcinoma	1103
Buserelin: Gonatropin-releasing hormone (GnRH) agonists - Risk of depression	1112
Cabergoline: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Camphor for external or inhaled use – Risk of toxic effects after accidental oral intake	1007
Carbamazepine – Risk of skin reactions in association with HLA-B*1502 allele in patients from some Asian populations and with HLA-A*3101 allele in patients of European and Japanese descent	1207
Carbamazepine: Active substances with a known risk of Stevens-Johnson syndrome and toxic epidermal necrolysis	1109
Carbamazepine: Antiepileptics – Risk of bone disorders	1110
Carbapenems: Valproic acid – Interaction with carbapenems	1001
Carbidopa: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Carteolol: Beta-blockers for ophthalmic use – Risk of systemic adverse reactions	1106
Catechol-O-methyltransferase inhibitors: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Ceftriaxone - Harmonisation of contraindications in newborns and risk of calcium-ceftriaxone precipitation when administered/mixed with solutions containing calcium	0909
Cerivastatin (marketing authorisation withdrawn): Fusidic acid – Risk of rhabdomyolysis due to interaction with HMG-CoA reductase inhibitors	1107

Topic Title	Issue Number
Chlorpromazine: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Chlorpromazine: Antipsychotics - Risk of venous thromboembolism	0910
Chlorprothixene: Antipsychotics - Risk of venous thromboembolism	0910
CHMP Guideline on Duplicate Detection and Management of Individual Cases and Individual Case Safety Reports	1003
CHMP Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In-vivo Clinical Use (EMA/CHMP/BMWP/ 86289/2010)	1112
Ciclesonide: Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1011
Cisplatin – Risk of increased ototoxicity in patients with genetic variants of TMPT and CO	1006
Citalopram – Risk of QT interval prolongation	1110
Citalopram: Antidepressants – Risk of bone fractures	1003
Citalopram: Serotonergic antidepressants – Risk of persistent pulmonary hypertension of the newborn	1003
Citalopram: SSRIs – Update of product information to reflect animal data on the effect on sperm quality and an evaluation of its human relevance	1203
Clenbuterol: Short-acting beta agonists - Risk of myocardial ischaemia	0910
Clodronic acid: Bisphosphonates for oral use – Risk of oesophageal irritation but insufficient evidence on causal relationship with oesophageal cancer	1207
Clodronic acid: Bisphosphonates for oral use – Risk of oesophageal irritations but insufficient evidence to conclude a causal relationship with oesophageal cancer	1010
Clomipramine: Antidepressants – Risk of bone fractures	1003
Clopidogrel: Omeprazole and esomeprazole – Risk of reduced plasma levels of clopidogrel due to interaction	1003
Clotiapine: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Clotiapine: Antipsychotics - Risk of venous thromboembolism	0910
Clozapine: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Clozapine: Antipsychotics - Risk of venous thromboembolism	0910
CMD(h) & PhVWP Best Practice Guide on Communication and Implementation of Safety Information	1006
Combined oral contraceptives containing ethinylestradiol + drospirenone (YASMIN, YASMINELLE and other products) – Risk of venous thromboembolism (VTE)	1105
Combined oral contraceptives containing ethinylestradiol 30µg + drospirenone (YASMIN/YIRA – Risk of venous thromboembolism (VTE)	1201
COMT inhibitors: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1003
Co-opted PhVWP Members: Appointment of three new Co-opted PhVWP Members	1207
Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1002
COSMOFER: Low-molecular-weight iron dextran – Risk of allergic reactions	1011
Cyamemazine: Antipsychotics - Risk of venous thromboembolism	1005
Cyproterone acetate - Risk of meningioma	0910
Deficiencies in Roche's adverse reaction reporting	0911
Dexamethasone: Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1206
Dexlansoprazole: Proton-pump inhibitors – Risk of hypomagnesaemia with long-term use	1011
Dipyridamole in combination with acetylsalicylic acid – No evidence for increased risk of ischaemic stroke versus acetylsalicylic acid alone in the European population	1112
Direct Healthcare Professional Communications (DHPCs): Research in the Netherlands	1004
Diuretics, high-ceiling – Evidence does not confirm risk of basal cell carcinoma	1011
Dixyrazine: Antipsychotics - Risk of venous thromboembolism	1103
DOCETAXEL ACTAVIS – Risk of infusion site reactions	0910
Domperidone - Risk of cardiac disorders	1202
Domperidone - Risk of cardiac disorders	1110
Donepezil – Risk of neuroleptic malignant syndrome but insufficient evidence on causal relationship with serotonin syndrome	1110
Dopamine agonists: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Dosulepin: Antidepressants – Risk of bone fractures	1207
Doxepin: Antidepressants – Risk of bone fractures	1003
Driving under the Influence of Drugs, Alcohol and Medicines - The Integrated Project DRUID under the European Commission's 6th Framework Programme	1003
Droperidol: Antipsychotics - Risk of venous thromboembolism	1106
Drospirenone: Ethinylestradiol + drospirenone-containing oral contraceptives (YASMIN, YASMINELLE and other products) – Risk of venous thromboembolism	0910
Drospirenone: YASMIN/YIRA (ethinylestradiol 30µg + drospirenone) – Risk of venous thromboembolism	1105
DRUID: Driving under the Influence of Drugs, Alcohol and Medicines - The Integrated Project DRUID under the European Commission's 6th Framework Programme	1201
Duloxetine: Serotonergic antidepressants – Risk of persistent pulmonary hypertension of the newborn	1003
Election of PhVWP Vice-Chairperson	1003
ENCePP: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance	1009
Enoxacin: Fluoroquinolones – Risk of QT interval prolongation	1011
Entacapone: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1012
Ephedrine: Short-acting beta agonists - Risk of myocardial ischaemia	1207
	0910

Topic Title	Issue Number
EPIPEN: Adrenaline-containing auto-injectors – Risk of failure of self-injection due to labelling	1010
Epoetins - Risk of pure red cell aplasia	0912
EPREX: Epoetins - Risk of pure red cell aplasia	0912
Erythropoietin, recombinant human: Epoetins - Risk of pure red cell aplasia	0912
Escitalopram – Risk of QT interval prolongation	1111
Escitalopram: Antidepressants – Risk of bone fractures	1003
Escitalopram: Serotonergic antidepressants – Risk of persistent pulmonary hypertension of the newborn	1003
Escitalopram: SSRIs – Update of product information to reflect animal data on the effect on sperm quality and an evaluation of its human relevance	1203
Esomeprazole and omeprazole – Risk of reduced plasma levels of clopidogrel due to interaction	1003
Esomeprazole: Pantoprazole and other proton pump inhibitors – Evidence does not confirm increased risk of pneumonia	1207
Esomeprazole: Proton pump inhibitors – Risk of bone fracture	1203
Esomeprazole: Proton-pump inhibitors – Risk of hypomagnesaemia with long-term use	1112
Etacrynic acid: High-ceiling diuretics – Evidence does not confirm risk of basal cell carcinoma	1103
Ethinylestradiol + drospirenone-containing oral contraceptives (YASMIN, YASMINELLE and other products) – Risk of venous thromboembolism	1105
Ethinylestradiol 30µg + drospirenone (YASMIN/YIRA) – Risk of venous thromboembolism	1201
Ethinylestradiol 30µg + drospirenone (YASMIN/YIRA) – Risk of venous thromboembolism	1003
Etidronic acid: Bisphosphonates for oral use – Risk of oesophageal irritation but insufficient evidence on causal relationship with oesophageal cancer	1207
Etidronic acid: Bisphosphonates for oral use – Risk of oesophageal irritations but insufficient evidence to conclude a causal relationship with oesophageal cancer	1010
Eu2P - European Programme in Pharmacovigilance and Pharmacoepidemiology	1007
EudraVigilance Access Policy for Medicines for Human Use	1107
European Medicines Agency's Transatlantic Workshop on Drug-Related Progressive Multifocal Leukoencephalopathy	1102
European Network of Centres for Pharmacovigilance and Pharmacovigilance (ENCePP)	1011
European Programme in Pharmacovigilance and Pharmacoepidemiology (Eu2P)	1007
Fenoterol: Short-acting beta agonists - Risk of myocardial ischaemia	0910
FERRISAT: Low-molecular-weight iron dextran – Risk of allergic reactions	1005
Finasteride - Risk of male breast cancer	0910
Flunisolide: Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1011
Fluoroquinolones – Risk of QT interval prolongation	1012
Fluoxetine – Risk of cardiovascular birth defects	1002
Fluoxetine: Antidepressants – Risk of bone fractures	1003
Fluoxetine: Serotonergic antidepressants – Risk of persistent pulmonary hypertension of the newborn	1003
Fluoxetine: SSRIs – Update of product information to reflect animal data on the effect on sperm quality and an evaluation of its human relevance	1203
Flupenthixol: Antipsychotics - Risk of venous thromboembolism	0910
Fluphenazine: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Fluphenazine: Antipsychotics - Risk of venous thromboembolism	0910
Fluspirilene: Antipsychotics - Risk of venous thromboembolism	0910
Fluticasone: Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1011
Fluvastatin: Fusidic acid – Risk of rhabdomyolysis due to interaction with HMG-CoA reductase inhibitors	1107
Fluvastatin: HMG-CoA reductase inhibitors - Risk of new onset diabetes	1112
Fluvastatin: HMG-CoA reductase inhibitors - Risks of sleep disturbances, memory loss, sexual dysfunction, depression, interstitial lung disease and micturition disorders	0911
Fluvoxamine: Antidepressants – Risk of bone fractures	1003
Fluvoxamine: Serotonergic antidepressants – Risk of persistent pulmonary hypertension of the newborn	1003
Fluvoxamine: SSRIs – Update of product information to reflect animal data on the effect on sperm quality and an evaluation of its human relevance	1203
Formoterol (OXIS TURBOHALER or OXIS TURBUHALER): Effect of physical impact on accuracy of dose delivery and recommended 100 dose pack size for BRICANYL TURBOHALER (terbutaline)	1104
Formoterol: Long-acting beta2-adrenoceptor agonist bronchodilators – Review of safety in the management of asthma	1010
Fosphenytoin: Phenytoin and fosphenytoin - Risk of Stevens-Johnson syndrome in association with HLA-B*1502 allele	0911
Furosemide: High-ceiling diuretics – Evidence does not confirm risk of basal cell carcinoma	1103
Fusidic acid – Risk of rhabdomyolysis due to interaction with HMG-CoA reductase inhibitors	1107
GEMCITABINE ACTAVIS – Risk of adverse reactions due to increased alcohol concentration after reconstitution error	1106
Gemifloxacin: Fluoroquinolones – Risk of QT interval prolongation	1012
Gonadotropin-releasing hormone (GnRH) agonists – Risk of depression	1112
Good Pharmacovigilance Practices (GVP) for the EU	1206
Good Pharmacovigilance Practices (GVP) for the EU – Modules IV and XV for public consultation	1207
Good Pharmacovigilance Practices (GVP) for the EU – Release for public consultation	1202
Goserelin: Gonadotropin-releasing hormone (GnRH) agonists - Risk of depression	1112
Guide on the interpretation of spontaneous case reports of suspected adverse reactions to medicines	1106

Topic Title	Issue Number
Guideline on the Conduct of Pharmacovigilance for Vaccines for Pre- and Post-Exposure Prophylaxis against Infectious Diseases (EMA/CHMP/PhVWP/503449/2007)	0909
GVP: Good Pharmacovigilance Practices for the EU	1206
GVP: Good Pharmacovigilance Practices for the EU – Modules IV and XV for public consultation	1207
GVP: Good Pharmacovigilance Practices for the EU – Release for public consultation	1202
Haloperidol: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Haloperidol: Antipsychotics - Risk of venous thromboembolism	0910
Hexoprenaline: Short-acting beta agonists - Risk of myocardial ischaemia	0910
High-ceiling diuretics – Evidence does not confirm risk of basal cell carcinoma	1103
Histrelin: Gonatropin-releasing hormone (GnRH) agonists - Risk of depression	1112
HMG-CoA reductase inhibitors - Risk of new onset diabetes	1112
HMG-CoA reductase inhibitors (statins) - Risks of sleep disturbances, memory loss, sexual dysfunction, depression, interstitial lung disease and micturition disorders	0911
HMG-CoA reductase inhibitors and fusidic acid – Risk of rhabdomyolysis due to interaction	1107
Hormone Replacement Therapy containing oestrogen with and without progesterone – 3rd revision of Core Summary of Product Characteristics	1001
Hydrochlorothiazide – Use during breast-feeding	1106
Ibandronic acid: Bisphosphonates for oral use – Risk of oesophageal irritation but insufficient evidence on causal relationship with oesophageal cancer	1207
Ibandronic acid: Bisphosphonates for oral use – Risk of oesophageal irritations but insufficient evidence to conclude a causal relationship with oesophageal cancer	1010
ICH Implementation Guide (ICH-E2B(R3)) for the International Standard for the Electronic Transmission of Individual Case Safety Reports	1110
ICH: Meetings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) in June 2011	1106
ICH: Meetings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) in November 2010	1012
ICH: Meetings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use in June 2011	1106
ICH-E2C (R2) guideline on periodic benefit-risk evaluation report (PBRER)	1204
Imipramine: Antidepressants – Risk of bone fractures	1003
Influenza pandemic: Pharmacovigilance for medicinal products used against novel swine-origin Influenza A (H1N1) virus in humans	0909
	0910
	0911
	0912
	1001
	1002
Insulin products, inc insulin analogues – Consistent product information regarding the risk of heart failure with concomitant use of pioglitazone	1101
International Conference on Pharmacoepidemiology (ICPE)	0910
Iron dextran, low-molecular-weight: Risk of allergic reactions	1005
Isosulfan Blue: Blue dyes – Risk of serious allergic reactions	1204
Isotretinoin – Risk of psychiatric reactions	1104
Isotretinoin for oral use – Risk of erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis	1003
Lamotrigine – Evidence <u>not</u> confirming signal of increased risk of sudden unexpected death (SUDEP) in epilepsy (SUDEP) with lamotrigine	1205
Lamotrigine – No evidence of increased risk of fatal liver failure	1003
Lamotrigine – Risk of aseptic meningitis	1009
Lamotrigine: Active substances with a known risk of Stevens-Johnson syndrome and toxic epidermal necrolysis	1109
Lamotrigine: Antiepileptics – Risk of bone disorders	1110
Lansoprazole: Pantoprazole and other proton pump inhibitors – Evidence does <u>not</u> confirm increased risk of pneumonia	1207
Lansoprazole: Proton pump inhibitors – Risk of bone fracture	1203
Lansoprazole: Proton-pump inhibitors – Risk of hypomagnesaemia with long-term use	1112
Latanoprost – No evidence for risk of malignant melanomas of the eye and skin	1004
Leuprorelin: Gonatropin-releasing hormone (GnRH) agonists - Risk of depression	1112
Levobunolol: Beta-blockers for ophthalmic use – Risk of systemic adverse reactions	1106
Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Levofloxacin: Fluoroquinolones – Risk of QT interval prolongation	1012
Levomopromazine: Antipsychotics - Risk of venous thromboembolism	0910
Lisuride: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Lofepamine: Antidepressants – Risk of bone fractures	1003
Long-acting beta ₂ -adrenoceptor agonist bronchodilators formoterol and salmeterol – Review of safety in the management of asthma	1010
Lovastatin: Fusidic acid – Risk of rhabdomyolysis due to interaction with HMG-CoA reductase inhibitors	1107
Lovastatin: HMG-CoA reductase inhibitors - Risk of new onset diabetes	1112
	1203
Lovastatin: HMG-CoA reductase inhibitors - Risks of sleep disturbances, memory loss, sexual dysfunction, depression, interstitial lung disease and micturition disorders	0911
Low-molecular-weight iron dextran – Risk of allergic reactions	1005

Topic Title	Issue Number
Loxapine: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Loxapine: Antipsychotics - Risk of venous thromboembolism	0910
Medical Dictionary for Drug Regulatory Activities (MedDRA) – List of Important Medical Event Terms (IME)	1007
Medical Dictionary for Drug Regulatory Activities (MedDRA) - Preparation of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Meetings in October 2009	0910
Meloxicam: Active substances with a known risk of Stevens-Johnson syndrome and toxic epidermal necrolysis	1109
Melperone: Antipsychotics - Risk of venous thromboembolism	0910
Methotrexate – Risk of overdose due to erroneous daily intake of the weekly dose in rheumatologic and dermatologic indication	1112
Metipranolol: Beta-blockers for ophthalmic use – Risk of systemic adverse reactions	1106
Mirtazapine: Serotonergic antidepressants – Risk of persistent pulmonary hypertension of the newborn	1003
Molindone: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Mometasone: Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1011
Montelukast – Reports of psychiatric and behaviour-related adverse reactions	1102
Montelukast - Risk of psychiatric adverse reactions in children	1112
Moxifloxacin: Fluoroquinolones – Risk of QT interval prolongation	1012
Nafarelin: Gonadotropin-releasing hormone (GnRH) agonists - Risk of depression	1112
Nanomedicines: 1 st EMA Scientific Workshop on Nanomedicines on 2-3 September 2010	1009
Nevirapine: Active substances with a known risk of Stevens-Johnson syndrome and toxic epidermal necrolysis	1109
New legislation for pharmacovigilance in the European Union	1009 1101
New term of PhVWP Patient Observers	1105
Norfloxacin: Fluoroquinolones – Risk of QT interval prolongation	1012
Nortriptyline: Antidepressants – Risk of bone fractures	1003
Notice to Applicants - A Guideline on Summary of Product Characteristics	0910
Oestrogen: Hormone Replacement Therapy containing oestrogen with and without progesterone – 3rd revision of Core Summary of Product Characteristics	1001
Ofloxacin: Fluoroquinolones – Risk of QT interval prolongation	1012
Omeprazole and esomeprazole – Risk of reduced plasma levels of clopidogrel due to interaction	1003
Omeprazole: Pantoprazole and other proton pump inhibitors – Evidence does <u>not</u> confirm increased risk of pneumonia	1207
Omeprazole: Proton pump inhibitors – Risk of bone fracture	1203
Omeprazole: Proton-pump inhibitors – Risk of hypomagnesaemia with long-term use	1112
Orciprenaline: Short-acting beta agonists - Risk of myocardial ischaemia	0910
Oxcarbazepine – Risk of skin reactions potentially associated with HLA-A*3101 and HLA-B*1502 alleles	1207
Oxcarbazepine: Antiepileptics – Risk of bone disorders	1110
OXIS TURBOHALER (or OXIS TURBUHALER) (formoterol): Effect of physical impact on accuracy of dose delivery and recommended 100 dose pack size for BRICANYL TURBOHALER (terbutaline)	1104
Pantoprazole and other proton pump inhibitors – Evidence does <u>not</u> confirm increased risk of pneumonia	1207
Pantoprazole: Proton pump inhibitors – Risk of bone fracture	1203
Pantoprazole: Proton-pump inhibitors – Risk of hypomagnesaemia with long-term use	1112
Paracetamol – Available evidence does not support a causal relationship between paracetamol and asthma in children after exposure in pregnancy or use in early infancy	1102
Paracetamol: PERFALGAN 10 mg/ml solution for infusion – Risk of dosing errors in infants resulting in overdose with serious outcome	1003
Paracetamol: PERFALGAN 10 mg/ml solution for infusion – Risk of medication errors resulting in overdose	1203
Paroxetine: Antidepressants – Risk of bone fractures	1003
Paroxetine: Serotonergic antidepressants – Risk of persistent pulmonary hypertension of the newborn	1003
Paroxetine: SSRIs – Update of product information to reflect animal data on the effect on sperm quality and an evaluation of its human relevance	1203
Patent Blue V: Blue dyes – Risk of serious allergic reactions	1204
Pefloxacin: Fluoroquinolones – Risk of QT interval prolongation	1012
Penfluridol: Antipsychotics - Risk of venous thromboembolism	0910
PERFALGAN (paracetamol) 10 mg/ml solution for infusion – Risk of dosing errors in infants resulting in overdose with serious outcome	1003
PERFALGAN (paracetamol) 10 mg/ml solution for infusion – Risk of medication errors resulting in overdose	1203
Pergolide: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Pericyazine: Antipsychotics - Risk of venous thromboembolism	0910
Perphenazine: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Perphenazine: Antipsychotics - Risk of venous thromboembolism	0910
Phenobarbital: Active substances with a known risk of Stevens-Johnson syndrome and toxic epidermal necrolysis	1109
Phenobarbital: Antiepileptics – Risk of bone disorders	1110

Topic Title	Issue Number
Phenytoin and fosphenytoin - Risk of Stevens-Johnson syndrome in association with HLA-B*1502 allele	0911
Phenytoin: Active substances with a known risk of Stevens-Johnson syndrome and toxic epidermal necrolysis	1109
Phenytoin: Antiepileptics – Risk of bone disorders	1110
Pimecrolimus – Concerns over off-label use	1207
Pimozide: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Pimozide: Antipsychotics - Risk of venous thromboembolism	0910
Pioglitazone: Insulin products – Consistent product information regarding the risk of heart failure with concomitant use of pioglitazone	1101
Pipamperone: Antipsychotics - Risk of venous thromboembolism	0910
Pipothiazine: Antipsychotics - Risk of venous thromboembolism	0910
Pirbuterol: Short-acting beta agonists - Risk of myocardial ischaemia	0910
Piretanide: High-ceiling diuretics – Evidence does not confirm risk of basal cell carcinoma	1103
Piribedil: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Piroxicam: Active substances with a known risk of Stevens-Johnson syndrome and toxic epidermal necrolysis	1109
Pitavastatin: HMG-CoA reductase inhibitors - Risk of new onset diabetes	1112
Plantago isphagula (syn.: P.ovata) – Risk of allergic reactions after prolonged occupational exposure	1107
Plantago ovata (syn.: P. isphagula) – Risk of allergic reactions after prolonged occupational exposure	1107
PPIs: Pantoprazole and other proton pump inhibitors – Evidence does <u>not</u> confirm increased risk of pneumonia	1207
Pramipexole: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Pravastatin: Fusidic acid – Risk of rhabdomyolysis due to interaction with HMG-CoA reductase inhibitors	1107
Pravastatin: HMG-CoA reductase inhibitors - Risk of new onset diabetes	1112
Pravastatin: HMG-CoA reductase inhibitors - Risks of sleep disturbances, memory loss, sexual dysfunction, depression, interstitial lung disease and micturition disorders	0911
Prazepam – Not contraindicated in glaucoma	1207
Prednisolone: Corticosteroids for inhalational or intranasal use – Risk of psychiatric, behavioural and other systemic adverse reactions	1011
Primidone: Antiepileptics – Risk of bone disorders	1110
Procaterol: Short-acting beta agonists - Risk of myocardial ischaemia	0910
Prochlorperazine: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Prochlorperazine: Antipsychotics - Risk of venous thromboembolism	0910
Progesterone: Hormone Replacement Therapy containing oestrogen with and without progesterone – 3rd revision of Core Summary of Product Characteristics	1001
Promazine: Antipsychotics - Risk of venous thromboembolism	0910
Propylthiouracil - Risk of serious liver injury	0911
Prothipendyl: Antipsychotics - Risk of venous thromboembolism	0910
Proton pump inhibitors – Risk of bone fracture	1203
Proton pump inhibitors: Pantoprazole and other proton pump inhibitors – Evidence does <u>not</u> confirm increased risk of pneumonia	1207
Proton-pump inhibitors – Risk of hypomagnesaemia with long-term use	1112
Proton-pump inhibitors: Omeprazole and esomeprazole – Risk of reduced plasma levels of clopidogrel due to interaction	1003
Prulifloxacin: Fluoroquinolones – Risk of QT interval prolongation	1012
PULMICORT TURBOHALER (or PULMICORT TURBUHALER) (budesonide): Effect of physical impact on accuracy of dose delivery and recommended 100 dose pack size for BRICANYL TURBOHALER (terbutaline)	1104
Quetiapine: Antipsychotics - Risk of venous thromboembolism	0910
Quinagolide: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Rabeprazole: Pantoprazole and other proton pump inhibitors – Evidence does <u>not</u> confirm increased risk of pneumonia	1207
Rabeprazole: Proton pump inhibitors – Risk of bone fracture	1203
Rabeprazole: Proton-pump inhibitors – Risk of hypomagnesaemia with long-term use	1112
Reboxetine – Confirmation of positive benefit-risk balance	1107
RELENZA Inhalation Powder (zanamivir) – Death of a patient after off-label use (nebulisation)	0910
Reproterol: Short-acting beta agonists - Risk of myocardial ischaemia	0910
Research on Direct Healthcare Professional Communications (DHPCs) in the Netherlands	1011
Risedronic acid: Bisphosphonates for oral use – Risk of oesophageal irritation but insufficient evidence on causal relationship with oesophageal cancer	1207
Risedronic acid: Bisphosphonates for oral use – Risk of oesophageal irritations but insufficient evidence to conclude a causal relationship with oesophageal cancer	1010
Risperidone: Antipsychotics – Risk of extrapyramidal effects and withdrawal symptoms in newborns after exposure during pregnancy	1107
Risperidone: Antipsychotics - Risk of venous thromboembolism	0910
Ritodrine: Short-acting beta agonists - Risk of myocardial ischaemia	0910
Roche: Deficiencies in Roche's adverse reaction reporting	1206
Ropinirole: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207
Rosuvastatin – Risk of diabetes	1005
Rosuvastatin – Risk of gynaecomastia	1111
Rosuvastatin: Fusidic acid – Risk of rhabdomyolysis due to interaction with HMG-CoA reductase inhibitors	1107

Topic Title	Issue Number
Rosuvastatin: HMG-CoA reductase inhibitors - Risk of new onset diabetes	1112
Rosuvastatin: HMG-CoA reductase inhibitors - Risks of sleep disturbances, memory loss, sexual dysfunction, depression, interstitial lung disease and micturition disorders	0911
Rotigotine: Levodopa, dopamine agonists and COMT inhibitors – Risk of impulse control disorders	1207